Case Number: 5-104-047(A), Year Published: 2004, Revision Date: August 16, 2005
HBS Number: KEL014
New Products, Pioneering Strategy, Pricing
This case examines the launch of Xigris, a breakthrough new pharmaceutical product for the treatment of sepsis. In the (A) case, the newly appointed head of marketing for Xigris is reviewing the launch plan. In the (B) case, Eli Lilly receives FDA approval and proceeds to market.
Return to Search Results